Alterations in urinary metals following pulsed 660 nm photobiomodulation in a pediatric patient with autism spectrum disorder: a case report - Report - MDSpire
Advertisement
Alterations in urinary metals following pulsed 660 nm photobiomodulation in a pediatric patient with autism spectrum disorder: a case report
Changes in Urinary Metal Levels After 660 nm Photobiomodulation in a Child Diagnosed with Autism Spectrum Disorder: A Case Study
Overview
This case study reports an increase in urinary aluminum levels following pulsed 660 nm photobiomodulation (PBM) in a child with autism spectrum disorder (ASD).
Background
Aluminum exposure has been linked to neurodevelopmental disorders, including ASD. Current treatment options for heavy metal mobilization, such as chelation therapy, carry risks, particularly in pediatric populations. Nonchelation strategies may influence metal excretion.
Data Highlights
Time Point
Urinary Aluminum (µg/g creatinine)
Baseline 1
10.0
Baseline 2
9.8
Day 3
58
Day 7
98
Follow-up
49
Key Findings
Initial urinary aluminum levels were stable at 10.0 and 9.8 µg/g creatinine.
After PBM, urinary aluminum levels increased to 58 µg/g on Day 3 and peaked at 98 µg/g on Day 7.
At follow-up, urinary aluminum remained elevated at 49 µg/g creatinine.
Mercury levels exceeded reference values in all specimens, including baseline, with a follow-up level of 8.4 µg/g creatinine.
Clinical Implications
The observed increase in urinary aluminum following PBM should be documented in patients undergoing such interventions.
Conclusion
This case study provides evidence of increased urinary aluminum excretion following PBM in a child with ASD.
